Asset profile
TH-SC01
Cell therapy
Evidence outlook · registrational
Crohn's Disease: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-12-28.
NCT05626023: The study was a small, sequential, single-arm open-label trial with no randomization, blinding, or comparator, enrolling 9 participants. Its primary endpoints were adverse events, dose-limiting toxicity, and maximum tolerated dose, and the trial results are not available, so it provides limited controlled evidence for TH-SC01.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.